Goy A, et al. - In phase 1b portion of this open-label, dose-escalation (3+3+3 design) study, researchers sought for the maximum tolerated dose (MTD) and preliminary safety and activity of the combination of ibrutinib, lenalidomide, and rituximab in transplant-ineligible adults with histologically confirmed relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after {greater than or equal to}1 prior therapy. Due to dose-limiting toxicities, a de-escalation cohort (10 mg lenalidomide) was initiated and, with subsequent re-escalation up to 25 mg lenalidomide, the MTD was not reached. Outcomes suggest manageable safety profile of the combination in patients with relapsed/refractory DLBCL. Promising and durable activity of the combination in relapsed/refractory DLBCL was reported. This was particularly observed in patients with non-germinal center B-cell DLBCL